What Happens When a $2 Million Gene Therapy Is Not Enough

Baby Ben Kutschke was diagnosed at 3 months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.

Related Keywords

Berwyn ,Illinois ,United States ,Columbus ,Ohio ,Switzerland ,Lebanon ,Russia ,Kazakhstan ,Chicago ,Virginia ,Americans ,Roger Hajjar ,Elizabeth Kutschke ,Jerry Mendell ,Amanda Cook ,Russell Butterfield ,Stacie Dusetzina ,Ben Kutschke ,Maha Radhakrishnan ,Vasant Narasimhan ,Sitra Tauscher Wisniewski ,Roche Evrysdi ,Caroline Humer ,Steven Pearson ,Eric Cox ,Sara Ledwith ,Sree Chaguturu ,University Of Utah Health ,Institute For Clinical ,Institute For Human Data Science ,Unitedhealth Group ,Novartis ,Drug Administration ,Aetna ,Brigham Gene Cell Therapy Institute ,Reuters ,Nashville Vanderbilt University School Of Medicine ,Baby Ben Kutschke ,Human Data ,Novartis Gene ,Mass General Brigham Gene ,Cell Therapy ,Vanderbilt University School ,Economic Review ,Chief Medical Officer Maha Radhakrishnan ,Nationwide Children ,Utah Health ,Intermountain Primary Children ,Genomics Genomic Medicine ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Biologic Therapy ,Iologics ,Gene Therapy ,Muscular Atrophy ,Uscular Atrophies ,Spinal Muscular Atrophy ,Spinal Muscle Atrophy ,Drug Costs ,Drug Cost ,Medication Costs ,Drug Price ,Drug Pricing ,Medication Price ,Edication Pricing ,Genetics ,Health Care Economics ,